Cargando…

miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance

Background: Although several advancements have been achieved in research and treatment of lung adenocarcinoma in the past few years, the mechanism concerning cancerous cell migration and the cause of chemoresistance remains ambiguous. This research aimed to explore the impact of miR-1247-3p in lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jiansheng, Zheng, Xinyang, Tian, Xikun, Guan, Jun, Shi, Haizhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066213/
https://www.ncbi.nlm.nih.gov/pubmed/35517418
http://dx.doi.org/10.7150/jca.65167
_version_ 1784699758292500480
author Lin, Jiansheng
Zheng, Xinyang
Tian, Xikun
Guan, Jun
Shi, Haizhan
author_facet Lin, Jiansheng
Zheng, Xinyang
Tian, Xikun
Guan, Jun
Shi, Haizhan
author_sort Lin, Jiansheng
collection PubMed
description Background: Although several advancements have been achieved in research and treatment of lung adenocarcinoma in the past few years, the mechanism concerning cancerous cell migration and the cause of chemoresistance remains ambiguous. This research aimed to explore the impact of miR-1247-3p in lung adenocarcinoma. Methods: The mRNA expression of miR-1247-3p and STAT5A were conducted with qRT-PCR. Lentiviral vectors containing miR-1247-3p mimics and inhibitors were constructed. Cell migration were examined using Transwell assay. To observe chemotherapy resistance, Docetaxel, Doxorubicin, and Gefitinib were used. DIANA, miRDB, and TargetScan databases were applied to detect target genes. The binding sites were verified by double luciferase assay. Results: Low expression of miR-1247-3p was observed in lung adenocarcinoma tissues and cell lines. Its expression was lower in advanced stages. Cell migration of lung adenocarcinoma was inhibited by miR-1247-3p, and it could negatively regulate the process of chemoresistance. miR-1247-3p directly binds to 3' UTR of STAT5A mRNA, and it functions via targeting STAT5A. Conclusions: miR-1247-3p acted as a potential governor monitoring cell migration and chemotherapy resistance of LUAD by interacting with STAT5A. It has the potential to be exploited as novel therapeutic target for LUAD in the future.
format Online
Article
Text
id pubmed-9066213
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-90662132022-05-04 miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance Lin, Jiansheng Zheng, Xinyang Tian, Xikun Guan, Jun Shi, Haizhan J Cancer Research Paper Background: Although several advancements have been achieved in research and treatment of lung adenocarcinoma in the past few years, the mechanism concerning cancerous cell migration and the cause of chemoresistance remains ambiguous. This research aimed to explore the impact of miR-1247-3p in lung adenocarcinoma. Methods: The mRNA expression of miR-1247-3p and STAT5A were conducted with qRT-PCR. Lentiviral vectors containing miR-1247-3p mimics and inhibitors were constructed. Cell migration were examined using Transwell assay. To observe chemotherapy resistance, Docetaxel, Doxorubicin, and Gefitinib were used. DIANA, miRDB, and TargetScan databases were applied to detect target genes. The binding sites were verified by double luciferase assay. Results: Low expression of miR-1247-3p was observed in lung adenocarcinoma tissues and cell lines. Its expression was lower in advanced stages. Cell migration of lung adenocarcinoma was inhibited by miR-1247-3p, and it could negatively regulate the process of chemoresistance. miR-1247-3p directly binds to 3' UTR of STAT5A mRNA, and it functions via targeting STAT5A. Conclusions: miR-1247-3p acted as a potential governor monitoring cell migration and chemotherapy resistance of LUAD by interacting with STAT5A. It has the potential to be exploited as novel therapeutic target for LUAD in the future. Ivyspring International Publisher 2022-03-28 /pmc/articles/PMC9066213/ /pubmed/35517418 http://dx.doi.org/10.7150/jca.65167 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Lin, Jiansheng
Zheng, Xinyang
Tian, Xikun
Guan, Jun
Shi, Haizhan
miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance
title miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance
title_full miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance
title_fullStr miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance
title_full_unstemmed miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance
title_short miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance
title_sort mir-1247-3p targets stat5a to inhibit lung adenocarcinoma cell migration and chemotherapy resistance
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066213/
https://www.ncbi.nlm.nih.gov/pubmed/35517418
http://dx.doi.org/10.7150/jca.65167
work_keys_str_mv AT linjiansheng mir12473ptargetsstat5atoinhibitlungadenocarcinomacellmigrationandchemotherapyresistance
AT zhengxinyang mir12473ptargetsstat5atoinhibitlungadenocarcinomacellmigrationandchemotherapyresistance
AT tianxikun mir12473ptargetsstat5atoinhibitlungadenocarcinomacellmigrationandchemotherapyresistance
AT guanjun mir12473ptargetsstat5atoinhibitlungadenocarcinomacellmigrationandchemotherapyresistance
AT shihaizhan mir12473ptargetsstat5atoinhibitlungadenocarcinomacellmigrationandchemotherapyresistance